Tumor reduction by a small molecule human PD-1/PD-L1 inhibitor in a melanoma/PBMC co-implantation model.

被引：0

作者：

Vilalta, Marta ^{[1
]}

Punna, Sreenivas ^{[1
]}

Li, Shijie Chris ^{[1
]}

Malathong, Viengkham ^{[1
]}

Lange, Christopher ^{[1
]}

McMurtrie, Darren ^{[1
]}

Yang, Ju ^{[1
]}

Roth, Howard ^{[1
]}

McMahon, Jeffrey ^{[1
]}

Campbell, James J. ^{[1
]}

Ertl, Linda S. ^{[1
]}

Ong, Ryan ^{[1
]}

Wang, Yu ^{[1
]}

Zhao, Niky ^{[1
]}

Chhina, Vicky ^{[1
]}

Kumamoto, Alice ^{[1
]}

Yau, Simon ^{[1
]}

Dang, Tong ^{[1
]}

Zhang, Penglie ^{[1
]}

Schall, Thomas J. ^{[1
]}

Singh, Rajinder ^{[1
]}

机构：

[1] ChemoCentryx, Mountain View, CA USA

来源：

CANCER IMMUNOLOGY RESEARCH | 2020年 / 8卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B26

引用

页码：95 / 95

页数：1

共 50 条

[41] A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Girault, Isabelle
Adam, Julien
Shen, Shensi
Roy, Severine
Brard, Caroline
Faouzi, Sara
Routier, Emilie
Lupu, Jeremy
Warren, Sarah
Sorg, Kristina
Ong, SuFey
Morel, Pascale
Scoazec, Jean-Yves
Vagner, Stephan
Robert, Caroline
CLINICAL CANCER RESEARCH, 2022, 28 (03) : 518 - 525
[42] Targeting the PD-1/PD-L1 Axis in Human Vitiligo
Willemsen, Marcella
Melief, Cornelis J. M.
Bekkenk, Marcel W.
Luiten, Rosalie M.
FRONTIERS IN IMMUNOLOGY, 2020, 11
[43] PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Paiva, B.
Azpilikueta, A.
Puig, N.
Ocio, E. M.
Sharma, R.
Oyajobi, B. O.
Labiano, S.
San-Segundo, L.
Rodriguez, A.
Aires-Mejia, I.
Rodriguez, I.
Escalante, F.
de Coca, A. G.
Barez, A.
San Miguel, J. F.
Melero, I.
LEUKEMIA, 2015, 29 (10) : 2110 - 2113
[44] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Hunter, Katerina Ancevski
Socinski, Mark A.
Villaruz, Liza C.
MOLECULAR DIAGNOSIS & THERAPY, 2018, 22 (01) : 1 - 10
[45] Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
Jin, Shengzhe
Wang, Hongfei
Li, Yang
Yang, Jingwen
Li, Beibei
Shi, Peishang
Zhang, Xiangrui
Zhou, Xiaowen
Zhou, Xiuman
Niu, Xiaoshuang
Wu, Menghan
Wu, Yahong
Zhai, Wenjie
Qi, Yuanming
Gao, Yanfeng
Zhao, Wenshan
CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
[46] Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
Shengzhe Jin
Hongfei Wang
Yang Li
Jingwen Yang
Beibei Li
Peishang Shi
Xiangrui Zhang
Xiaowen Zhou
Xiuman Zhou
Xiaoshuang Niu
Menghan Wu
Yahong Wu
Wenjie Zhai
Yuanming Qi
Yanfeng Gao
Wenshan Zhao
Cell Communication and Signaling, 22
[47] Prospects for Targeting PD-1 and PD-L1 in Various Tumor Types
Kim, Joseph W.
Eder, Joseph Paul
ONCOLOGY-NEW YORK, 2014, 28 : 15 - 28
[48] The PD-1: PD-L1 pathway in the context of the osteosarcoma tumor microenvironment
Koirala, Pratistha
Gill, Jonathan
Roth, Michael
Piperdi, Sajida
Park, Amy
Poon, Vincent
Fremed, Michael
Hoang, Bang
Gorlick, Richard
CANCER RESEARCH, 2015, 75
[49] Interference of PD-1 and PD-L1 interaction with small-molecule inhibitors enhances the efficacy of tumor-specific CTLs
Redd, Priscilla S.
Lu, Chunwan
Ostrov, David
Lebedyeva, Iryna
Liu, Kebin
CANCER RESEARCH, 2018, 78 (13)
[50] Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC
Cerniglia, Michael
Klepadlo, Michal
Sheneman, David
Kim, Sunnie S.
BMJ CASE REPORTS, 2022, 15 (08)

← 1 2 3 4 5 →